Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Convention Name February 10, 2025 4:30 PM ET
Firm Individuals
Chris Anzalone – President & CEO
Bruce Given – Interim Chief Medical Scientist
Andy Davis – SVP & Head of International Cardio/Metabolic Franchise
James Hamilton – Chief Discovery & Translational Medication
Ken Myszkowski – CFO
Convention Name Individuals
Luca Issi – RBC Capital
David Lebowitz – Citi
Jasmine Fels – UBS
Maury Raycroft – Jefferies
Edward Tenthoff – PSC
Patrick Trucchio – H.C. Wainwright
Mayank Mamtani – B. Riley Securities
Andrea Newkirk – Goldman Sachs
Mani Foroohar – Leerink
Brendan Smith – TD Cowen
Jason Gerberry – Financial institution of America
Chris Anzalone
Thanks, Vince. Good afternoon, everybody, and thanks for becoming a member of us in the present day. Earlier in the present day, we introduced that the license and collaboration settlement with Sarepta Therapeutics is closed. Arrowhead expects to obtain a $500 million upfront fee within the subsequent 10 days and has already obtained $325 million by means of the acquisition by Sarepta of Arrowhead widespread inventory priced at $27.25 per share. Arrowhead may also obtain $250 million to be paid in annual installments of $50 million over 5 years and has the potential to obtain a further $300 million in near-term funds related to the continued enrollment of a Section I/II research of ARO-DM1, which we’re on observe to realize through the subsequent 12 months. Taken collectively, this provides as much as $1.375 billion in money funds.
We’re additionally eligible to obtain growth milestone funds of between $110 million and $410 million per program and gross sales milestone funds between $500 million and $700 million per program. The overall potential worth of this deal, together with upfront funds, fairness investments and potential milestone funds exceeds $11 billion. On prime of that, we’re additionally eligible to obtain tiered royalties on business gross sales. This was clearly a giant deal and a important step for
